Toripalimab and anlotinib for extensive stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs, toripalimab and anlotinib, as maintenance therapy after initial treatment for extensive stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from growing for as long as possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 79 years old.
- You have been diagnosed with extensive stage small cell lung cancer (cancer that has spread beyond the lung).
- You have not had any chemotherapy or immunotherapy for this stage of cancer yet.
- You have at least one tumor that can be measured on a scan and hasn't been treated with radiation in the last 6 months.
- Your general health is good enough to get out of bed and do light activities (ECOG score 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new maintenance therapy (adebrelimab plus apatinib) for people with extensive-stage small cell lung cancer who have already responded to initial chemotherapy and immunotherapy. The goal is to help keep the cancer from coming back longer.
This trial looks at whether adding a targeted therapy called anlotinib to immunotherapy maintenance can help people with extensive-stage small cell lung cancer who have already completed 4-6 cycles of standard chemoimmunotherapy without the cancer getting worse.
This trial tests a combination of a liposome-encased chemotherapy (irinotecan), a platinum drug, an immunotherapy, and a targeted therapy (anlotinib) as a maintenance treatment for extensive small cell lung cancer. The goal is to see if this approach helps keep the cancer from growing after initial successful treatment.
This study tests a combination of an oral targeted therapy (anlotinib) with a liposomal form of chemotherapy and an immunotherapy drug as maintenance treatment for extensive-stage small cell lung cancer after initial treatment. It aims to keep the cancer from growing again.
This trial tests a combination of two drugs (sacituzumab tirumotecan and anlotinib) for people with extensive-stage small cell lung cancer that has gotten worse after one prior treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, for people with extensive-stage small cell lung cancer that has worsened after at least two cycles of standard chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
Hear when a new Maintenance Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.